(Alliance News) - MaxCyte Inc on Wednesday said it has signed a new development and commercialisation agreement with biotechnology company KSQ Therapeutics.
MaxCyte shares were trading 8.1% higher in London on Wednesday midday at 122.20 pence each.
Under the deal, KSQ will gain the rights to use MaxCyte's flow electroporation technology and ExPERT instruments in KSQ's tumour-infiltrating lymphocyte programmes.
In return, the cell-based medicines and life sciences company will be eligible to receive milestone payments in addition to other licensing fees.
"Adoptive cell therapies hold significant potential to improve outcomes for patients that are otherwise unresponsive to current treatments," explained David Meeker, chief executive of KSQ.
"MaxCyte's technology will play an important role in enabling the further development of our engineered tumour-infiltrating lymphocyte programmes as we work to bring best-in-class, cell-based medicines forward for difficult to treat solid tumours."
"This is the fifth commercial licence we have signed this year, demonstrating MaxCyte is the partner of choice for leading technology companies, like KSQ, that are at the cutting edge of cell therapy and gene editing," added MaxCyte Chief Executive Doug Doerfler.
By Evelina Grecenko; [email protected]
Copyright 2019 Alliance News Limited. All Rights Reserved.